Tesamorelin vs Sermorelin: What the Research Compares

People search “tesamorelin vs sermorelin” as if one replaces the other. In the published research they are two designs of the same signal, with different histories. This page sets the two summaries side by side, shows what each body of work tested, and says where a direct comparison cannot be made.

Quick facts, side by side

• What each is: Sermorelin is a synthetic analog built from the first 29 amino acids of the 44-amino-acid GHRH, the shortest fragment that keeps full activity. Tesamorelin is a synthetic analog of human GHRH with the full 44-amino-acid sequence and a hexenoyl group, a six-carbon chain, attached to the first amino acid, tyrosine (FDA prescribing information).
• The receptor: Both are GHRH analogs. They act on the GHRH receptor on the pituitary cells that make growth hormone (Regulation of the pituitary somatotroph cell by GHRH and its receptor).
• How fast the body clears them: for tesamorelin, the prescribing information reports a mean elimination half-life of 11 minutes in healthy subjects. For sermorelin, the research describes a short circulating half-life on the order of minutes. These come from different sources and are not a head-to-head measurement.
• Human evidence for tesamorelin: two phase 3 trials and further randomized trials, all in adults with HIV who had extra abdominal fat. A 2026 meta-analysis pooled five of them (Badran et al., 2026).
• Human evidence for sermorelin: a long record in children with idiopathic growth hormone deficiency and in testing how well the pituitary can respond (Sermorelin review). In older adults the effect on measured growth hormone and IGF-1 is consistent across studies, while downstream effects are smaller and vary between studies.
• Approval: the FDA first approved tesamorelin as the prescription drug Egrifta in 2010. Its current label says it is indicated to reduce excess abdominal fat in adults with HIV who have lipodystrophy. Sermorelin was approved as Geref in 1990 and again in 1997, then withdrawn effective 2009-06-18. The Federal Register determination states it was not withdrawn for reasons of safety or effectiveness (Federal Register).

What the studies tested

Each item below tested one compound.

Tesamorelin, in adults with HIV and extra abdominal fat. In a randomized, placebo-controlled phase 3 trial of 412 participants, researchers measured a drop in visceral fat, the deep fat around the organs, in the tesamorelin group compared with placebo over 26 weeks (Falutz et al., 2007). A randomized trial of 50 participants over 6 months recorded reductions in both visceral fat and liver fat versus placebo (Stanley et al., 2014). The 2026 meta-analysis of five trials also listed the side effects logged in them, including joint pain, muscle pain and reactions at the site where it was given.

Sermorelin, in the pituitary and growth hormone axis. The work centers on the GHRH receptor and what the pituitary releases in response (Regulation of the pituitary somatotroph cell by GHRH and its receptor). Because sermorelin works through the receptor and not around it, the body’s natural brake on growth hormone release, somatostatin, still applies. Research groups have used that property to study how much a pituitary can respond. A blunted response is itself the measurement.

Where they differ, and where they cannot be compared

The two are built differently. Sermorelin is the shortened natural sequence. Tesamorelin is a full-length analog with a chemical addition at the start of the chain. Their human evidence also points at different questions: visceral and liver fat in one population for tesamorelin, pituitary responsiveness and a pediatric deficiency record for sermorelin.

Because the cited studies used different populations, different endpoints and different time frames, the numbers from one cannot be set against the numbers from the other. None of the studies cited on this page tested both compounds, so the work does not say which is the better tool for any given question. It says what each was used to ask.

Related research

• Tesamorelin: what the research shows
• Sermorelin research
• Tesamorelin vs Ipamorelin

Common questions

Are tesamorelin and sermorelin the same compound?

No. Both are analogs of GHRH and act on the same receptor, but sermorelin is built from the first 29 amino acids and tesamorelin carries the full 44 with a six-carbon chain added at the start.

Which one has an FDA approval?

Tesamorelin is approved as the prescription drug Egrifta for reducing excess abdominal fat in adults with HIV who have lipodystrophy. Sermorelin was approved as Geref and was withdrawn effective 2009-06-18 for commercial reasons, not for safety or effectiveness. Neither approval says anything about a research compound sold for laboratory use.

Have any studies compared the two directly?

None of the studies cited on this page tested both. Each tested one compound, in its own population and with its own endpoints.

Why are they so often mentioned together?

Both are GHRH analogs, so both are grouped under growth hormone signaling research. The grouping is real, but the designs, the evidence and the regulatory histories are separate.

For laboratory research use only. Not for human or animal consumption. This page summarizes published studies and is not medical advice.